Obesity

Biomarkers: Diabetes, Endocrinology and obesity

Molecular Biomarkers is demarcated as a characteristic that is accurately measured and gauged as an pointer of normal biological procedures, pathogenic procedures, or pharmacological responses to a pharmaceutical intervention. Biomarkers play an important part in leading clinical trials and treating patients. Advances in molecular diagnostics facilitate medical professionals make knowledgeable, scientifically valid choices. Procedural improvements from different fields, especially cancer, are beginning to show the method towards better models of diabetes pathogenesis and also molecular biomarker discovery. Diabetes is a major lifestyle disease and a leading cause of cardiovascular diseases. It is necessary to identify the potential of biomarkers associated with diabetes for the early detection of the disease and its proper management. Elevated blood pressure, elevated triglycerides, and low HDL cholesterol are some of the common biomarkers of diabetes, adiponectin, C-reactive protein (CRP), interleukin-2 receptor, ferritin  A being the other counterparts. Apart from these available and the known biomarkers, other potential biomarkers are also being searched and reported by researchers.

• Diabetes Mellitus: RBS, FBS, HbA1c, Retinal assessments
• Hypertension: BP, HR, Angiotensin I, II, Plasma Renin, Aldosterone
• Heart Failure: PRO-BNP
• Asthma/COPD: PFTs, Leukotrienes
• Cardiac Ischemia: Troponins, Myoglobins
• Endocrine Biomarkers: LCN2 (NGAL), HAVCR1 (KIM-1), HAMP (Hepcidin), GIP, PDGFB, PGF (PLGF), FLT1 (VEGFR1), FGF23, PYY, CCL2 (MCP1)